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Purpose: Donepezil, a drug frequently used to treat dementia, is mainly metabolized by
cytochrome P450 2D6 (CYP2D6). This study investigated the relationships between
CYP2D6 genotype and activity scores as well as predicted phenotype of plasma donepezil
concentrations in 86 Thai dementia participants.
Materials and Methods: CYP2D6 was genotyped using bead-chip technology (Luminex
xTAG® v.3). Steady-state trough plasma donepezil concentrations were measured using highperformance liquid chromatography.
Results: Sixteen genotypes were found but the most frequent genotypes detected among our
participants were CYP2D6*10/*10 (27.9%) and *1/*10 (26.7%). One-third of the participants
had an activity score of 1.25 which predicted that they were normal metabolizers. The overall
median (interquartile range) of plasma donepezil concentration was 51.20 (32.59–87.24) ng/mL.
Normal metabolizers (NMs) had lower plasma donepezil concentrations compared to intermedi
ate metabolizers (IMs) (41.15 (28.44–67.65) ng/mL vs 61.95 (35.25–97.00) ng/mL).
Multivariate analysis showed that CYP2D6 activity score (r2 = 0.50) and the predicted phenotype
(independent of dose) could predict the plasma donepezil concentration (r2 = 0.49).
Conclusion: Plasma donepezil concentration in NMs was lower compared to IMs.
Additional studies with larger sample size and use of next-generation sequencing as well
as its outcomes are warranted to confirm the benefit of using pharmacogenetic-guided
treatment for donepezil.
Keywords: CYP2D6, Luminex xTAG®, donepezil, dementia, pharmacogenetics

Introduction
Dementia is one of the major health problems worldwide. Alzheimer’s disease
(AD), the most common form of dementia, is a progressive neurological disorder
characterized by the loss of memory and impaired intellectual abilities. AD is
associated with the damage of cholinergic neurons in the brain and the decrease
in acetylcholine levels which interferes with the action of neurotransmitters.1–3 AD
patients suffer not only from memory loss, but also behavioral, thought, emotion
and self-care problems. It has been reported that the total treatment costs for AD
were at least nine billion dollars which is a huge burden to families and caregivers.4
Unfortunately, only 10–20% of the patients moderately respond to conventional
anti-dementia drugs.5
Acetylcholinesterase is a primary member of the cholinesterase enzyme family.
Acetylcholinesterase inhibitors (AChEIs) inhibit acetylcholinesterase from breaking
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down acetylcholine into choline and acetate. This in turn
results in an elevated level of acetylcholine in the central
nervous system, autonomic ganglia and neuromuscular
junctions for long periods of time. This action compen
sates for the loss of functioning brain cells in AD, resulting
in an improvement in the patient’s cognitive and beha
vioral functions.6,7 To date, AChEIs are the main drug
class for the treatment of dementia.5,8
Donepezil is one of the AChEIs currently approved by
the US Food and Drug Administration and the European
Medicines Agency for the treatment of cognitive manifes
tations of dementia. Donepezil is mainly metabolized
through cytochrome P450 2D6 (CYP2D6) enzyme in the
liver.9 CYP2D6 gene locus is highly polymorphic10 and
affects the pharmacokinetic properties of donepezil, result
ing in interindividual variability of the plasma concentra
tions of donepezil.7,9 There are four phenotype groups that
are commonly used to classify individuals as ultra-rapid
metabolizers (UMs), normal metabolizers (NMs), inter
mediate metabolizers (IMs), and poor metabolizers
(PMs). The Clinical Pharmacogenetic Consortium (CPIC)
has recently published recommendations for standardized
translation of genotype into phenotype which we have
adopted for this study.11
Genetic variability of CYP2D6 differs considerably
among various ethnic groups.12–15 CYP2D6 allele is fre
quently found in the Thai population.14–16 A study
reported the effects of CYP2D6*10 on plasma donepezil
concentration in Thai16 and Chinese17 patients with
dementia. However, those studies measured only
CYP2D6*2 and *10. As CYP2D6 is highly
polymorphic,10 it is unknown if other variations of
CYP2D6 can affect the dose and/or plasma concentration
of AChEIs, especially donepezil, in dementia patients.
Also, the calculation of the CYP2D6 activity score has
not been explored. These data are crucial in establishing
a specific guideline for the use of pre-emptive CYP2D6
genotyping to estimate AChEIs dose adjustment in this
specific group of patients.
This study investigated the relationship between
CYP2D6 genotype, activity score and genotype-predicted
phenotype on the steady-state of plasma donepezil con
centrations in a cohort of Thai patients suffering from mild
to moderate degrees of dementia.

Materials and Methods
This was a cross-sectional study conducted during the
maintenance phase of donepezil treatment in Thai
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participants with dementia. The study was approved by
the Ethics Committee of the Faculty of Medicine,
Chulalongkorn University (IRB number 201/59) and was
registered in the Thai Clinical Trial Registry
(TCTR20190924003). All participants or their legal guar
dians gave their informed consent before they participated
in the study. The study was conducted in accordance with
the Declaration of Helsinki and the guideline of the
International Conference on Harmonization in Good
Clinical Practice. Experimental work and data analyses
were performed at the Clinical Pharmacokinetics and
Pharmacogenomics Research Unit, Department of
Pharmacology, Faculty of Medicine, Chulalongkorn
University, Bangkok, Thailand.

Participants
A cohort of unrelated participants with mild to moderate
dementia who were continuously treated with donepezil
for at least 6 months were enrolled in the study. The
participants were recruited from the Dementia Outpatient
Clinic, King Chulalongkorn Memorial Hospital, Bangkok,
Thailand. Patients on other available AChEIs (galantamine
and rivastigmine) were excluded. The diagnosis of demen
tia was done by qualified dementia specialists at the
Dementia Outpatient Clinic, King Chulalongkorn
Memorial Hospital, Bangkok, Thailand. Comprehensive
neuropsychological tests were done to assess the severity
of the disease. The validated Thai Mental State
Examination (TMSE), Neuropsychiatry Inventory
Questionnaire (NPI-Q) and Thai version of Disability
Assessment for Dementia scale (DAD-T)18 were used to
assess the participant’s cognitive, psychological and beha
vioral functions. Also, other tests assessed whether the
participants were able to carry on with their daily routines
or not. All participants provided written informed consent
prior to the start of the study.

CYP2D6 Genotyping and Translation into
Phenotype
Genomic DNA was isolated from EDTA-treated whole
blood samples (3 mL) using a DNA extraction kit accord
ing to the manufacturer’s instruction (Invitrogen
PureLink® Genomic DNA Mini Kit, Life Technologies,
Carlsbad, CA, USA) and adjusted to 20 ng/µL. The
Luminex xTAG CYP2D6 kit version 3 (Luminex
Molecular Diagnostic, Toronto, ON, Canada) was used to
simultaneously detect 19 nucleotide variants of CYP2D6:

Pharmacogenomics and Personalized Medicine 2020:13
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1584C>G, 31G>A, 100C>T, 124G>A, 138insT, 883G>C,
1022C>T, 1660G>A, 1662G>C, 1708T>del, 1759G>T/A,
1847G>A,
2550A>del,
2616delAGA,
2851C>T,
2936A>C, 2989G>A, 3184G>A and 4181G>C (positions
are numbered using the NG_008376.3 RefSeq as recom
mended by the Pharmacogene Variation Consortium).19
Gene deletion of CYP2D6*5 and presence of duplications
were also detected. Samples were analyzed on a Luminex
200 IS system.
CYP2D6 genotypes were assigned using xTAG® Data
Analysis Software (TDAS CYP2D6 1.01) and translated into
phenotype using the CYP2D6 activity score system based on
the new standardized method that was recently recom
mended by CPIC.20 Briefly, the CYP2D6*10 allele received
a lower value for activity score calculation (ie, 0.25 vs 0.50).
CYP2D6 activity scores were then translated into phenotype
as follows: UMs (activity score >2.25), NMs (activity score
of 1.25 ≤ x ≤ 2.25), IMs (activity score of 0 < x < 1.25), and
PMs (activity score of 0).20

Determination of Plasma Donepezil
Concentrations
Steady-state trough plasma donepezil concentrations were
measured using a fully validated high performance liquid
chromatography (HPLC) technique as previously
described with some modifications.21,22
Sample preparation was done by liquid-liquid extraction.
One mL of plasma was combined with 10 μL of internal
standard solution (200 ng/mL rosiglitazone in acetonitrile)
and mixed for 1 minute. Then, 5 mL of methyl tert-butyl
ether was added and mixed for another 1 minute, followed
by centrifugation at 4500 rpm at 25°C for 10 minutes. The
organic layer was transferred into a 15 mL conical glass
tube. The supernatant was evaporated to dryness and recon
stituted with 150 µL of 50% methanol in de-ionized water.
The mixture was further centrifuged at 4500 rpm at 25°C for
15 minutes. Subsequently, 90 µL of the final reconstituted
solution was injected into the HPLC system (Shimadzu
Corporation, Japan). A reversed-phase chromatographic
separation was performed using a Luna 5u C18 column
(250 mm x 4.6 mm, 5 microns, Phenomenex, USA). The
analytes were eluted under gradient conditions using
a mobile phase composed of acetonitrile and 20 mM of
potassium dihydrogen phosphate with a pH of 5.85.
Compounds were detected with a fluorescence detector at
an excitation of 330 nm and an emission of 380 nm. A linear
calibration curve ranged from 2.5–112 ng/mL (r2 > 0.999).
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Intra- and inter-day precisions (at concentrations of 7.5, 40
and 80 µg/mL) were 0.59–2.78% and 7.76–10.82%, respec
tively. The accuracy was 86.44–113.10%. The mean abso
lute recovery was more than 93.09%. The total runtime was
23 minutes.
Plasma donepezil concentrations were reported as mea
sured concentrations (ng/mL), concentrations/dose per day
(ng/mL/mg/day) and concentration/dose per day/weight
(ng/mL/mg/kg/day).

Statistical Analysis
All analyses were performed using STATA version 14.0
(College Station, TX: StataCorp LP). Descriptive statistics
were employed to describe the basic demographic data and
CYP2D6 alleles whereas genotype frequencies were pre
sented as median (interquartile range) (median (IQR)).
Chi-square test, Fisher’s exact test, Mann–Whitney
U-test, or Kruskal Wallis test was performed according
to types and distributions of the data. Univariate and multi
variate analyses were carried out to explore the relation
ships between donepezil concentrations as a dependent
variable, and CYP2D6 genotype, activity score, predicted
phenotype, and other parameters as independent variables.
A p-value of <0.05 was considered significant.

Results
The characteristics of the 86 Thai elderly dementia parti
cipants were enrolled in the study (Table 1). All partici
pants had a similar degree of mild to moderate dementia
based on the comprehensive neuropsychological tests.
For all participants, the median donepezil dose was 5
(5–10) mg/day and median donepezil dose per day/weight
was 0.11 (0.09–0.19) mg/kg/day. Plasma donepezil con
centrations were significantly correlated with dose per day
and dose per day/weight (r2 = 0.77 and 0.70, respectively,
p < 0.01). The overall median plasma donepezil concen
tration was 50.12 (31.81–87.43) ng/mL. The median con
centration/dose per day was 7.76 (6.03–9.73) ng/mL/mg/
day and median concentration/dose per day/weight was
0.14 (0.11–0.21) ng/mL/mg/kg/day (Table 1).

CYP2D6 Genotypes: Relationships to
Plasma Donepezil Concentrations and
Donepezil Dose
Sixteen different genotypes were detected of which the
following CYP2D6 alleles were frequently found in our
study: CYP2D6*10 (n = 94, 54.7%), CYP2D6*1 (n = 37,
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Table 1 Patients’ Characteristics (n = 86)
Characteristics
Age (years)

78 (72–84)
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Sex (n (%))
Female

66 (77)

Male

20 (23)

Weight (kg)

54 (48–59)

Hemoglobin (g/dL)

12.7 (11.7–13.5)

White blood cell count (x103/µL)

6.05 (5.16–7.11)

Platelet count (x103/µL)

248 (207–282)

Blood urea nitrogen (mg/dL)

14 (11–9)

Serum creatinine (mg/dL)

0.89 (0.74–1.08)

Total protein (g/dL)

7.0 (6.7–7.5)

Albumin (g/dL)

4.0 (3.7–4.3)

Total bilirubin (mg/dL)

0.59 (0.42–0.75)

Direct bilirubin (mg/dL)

0.24 (0.17–0.28)

Aspartate aminotransferase (U/L)

22 (19–26)

Alanine aminotransferase (U/L)

16 (12–21)

Alkaline phosphatase (U/L)

72 (58–86)

Na (mmol/L)

140 (138–142)

K (mmol/L)

4.2 (3.9–4.5)

Cl (mmol/L)

106 (103–107)

HCO3 (mmol/L)

26 (24–27)

Drug dose
Donepezil dose (mg/day)

5 (5–10)

Donepezil dose/weight (mg/kg/day)

0.11 (0.09–0.19)

Plasma concentration
Plasma donepezil concentrations (ng/mL)

50.12 (31.81–87.43)

Concentration/dose (ng/mL/mg/day)

7.76 (6.03–9.73)

Concentration/dose/weight (ng/mL/mg/kg/day)

0.14 (0.11–0.21)

Diagnosis (n (%))
Alzheimer’s disease

55 (63.9)

Dementia with Lewy Bodies

4 (4.7)

Frontotemporal dementia

3 (3.5)

Mixed dementia

8 (9.3)

Vascular dementia

16 (18.6)

Thai Mental State Examination

22 (13–24)

Neuropsychiatric Inventory–Questionnaire

4 (0–11)

Disability Assessment for Dementia scale (Thai version)

26 (15–38)

Co-morbidity (n (%))
Hypertension

59 (69)

Dyslipidemia

31 (36)

Diabetes mellitus

18 (21)

Cardiovascular diseases (other than hypertension)

14 (16)

Chronic kidney disease

6 (7)

Note: All data are presented as median (interquartile range) unless otherwise stated.

21.5%), CYP2D6*2 (n = 17, 9.9%), CYP2D6*5 (n = 14,
8.1%), CYP2D6*41 (n = 7, 4.1%), CYP2D6*4 (n = 2,
1.2%), and CYP2D6*14B (n = 1, 0.6%) (Table 2).
CYP2D6*10/*10 was the most frequent genotype
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(27.9%) detected followed by CYP2D6*1/*10 (26.7%),
CYP2D6*5/*10 (10.5%) and CYP2D6*2/*10 (7.0%).
Plasma donepezil concentration, concentration/dose
per day and concentration/dose per day/weight were
highly variable amongst the CYP2D6 genotypes.
However, no statistically significant differences of the
plasma donepezil concentration, concentration/dose
per day, and concentration/dose per day/weight were seen
across the genotype groups (Table 2).

CYP2D6 Activity Scores and Predicted
Phenotypes: Relationships to Plasma
Donepezil Concentrations and Donepezil
Dose
The participants were classified into 7 groups based on
their CYP2D6 activity score (Table 3). The three most
commonly observed CYP2D6 activity score groups were
1.25 (34%), 0.5 (28%) and 0.25 (12%). Donepezil dose
per day was significantly different across the activity score
groups (p = 0.029).
About half of the participants in this study were pre
dicted to be NMs (n = 41, 48%) and the other half, IMs (n
= 45, 52%). NMs had lower plasma donepezil concentra
tions and donepezil dose per day compared to IMs (41.15
(28.44–67.65) vs 61.95 (35.25–97.00) ng/mL, p = 0.038
and 5 (5–10) vs 10 (5–10) mg/day, p = 0.035, respectively)
(Figure 1A and D). There were no significant differences
between NMs and IMs for concentration/dose per day
(6.78 (5.33–9.27) ng/mL/mg/day vs 8.50 (6.41–10.45)
ng/mL/mg/day), concentration/dose per day/weight (0.12
(0.10–0.20) vs 0.15 (0.11–0.21) ng/mL/mg/kg/day), and
dose per day/weight (0.10 (0.07–0.18) vs 0.16
(0.09–0.20) mg/kg/day) (Figure 1B, C and E).
From the multivariate analysis, the CYP2D6 activity
score and CYP2D6 predicted phenotype were predictors of
plasma donepezil concentration, independent of dose and
other factors (Table 4).

Discussion
This study investigated the relationships between CYP2D6
genotype, activity score, and predicted phenotype to the
steady-state plasma donepezil concentrations in Thai par
ticipants with mild to moderate dementia.
CYP2D6 allele frequencies in this study were in line with
previous studies conducted in Thai, East Asian and Chinese
populations.16,17,23,24 The distribution of CYP2D6 genotype in
this study was similar to those observed in Thai16 and Chinese
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Table 2 CYP2D6 Genotype, Plasma Donepezil Concentrations and Dose per Day (n = 86)
CYP2D6

CYP2D6

Plasma Donepezil

Concentration/

Concentration/

Dose

Dose/Weight

Genotype

Activity

N (%)

Concentrations

Dose (ng/mL/

Dose/Weight (ng/

(mg/day)

(mg/kg/day)

Score

(ng/mL)

mg/day)

mL/mg/kg/day)

*1/*1

2

4 (4.7)

66.47 (45.91–108.81)

5.92 (4.27–6.73)

0.11 (0.06–0.12)

10 (10–20)

0.18 (0.15–0.35)

*1/*2
*2/*2

2
2

3 (3.5)
1 (1.2)

67.99
30.39

7.16
6.08

0.14
0.10

10
5

0.17
0.09

*1/*41

1.5

1 (1.2)

41.72

8.34

0.19

5

0.11

*2/*14B
*2/*41

1.5
1.5

1 (1.2)
2 (2.3)

49.62
97.18

9.92
12.79

0.20
0.25

5
7.5

0.10
0.15

*1/*10
*2/*10

1.25
1.25

23 (26.7)
6 (7.0)

33.88 (14.74–63.49)
32.05 (20.56–53.03)

6.32 (5.06–9.44)
7.43 (6.59–8.92)

0.11 (0.09–0.21)
0.13 (0.11–0.16)

5 (2.5–10)
5 (2.5–6.25)

0.10 (0.05–0.16)
0.08 (0.04–0.13)

*2/*4

1

1 (1.2)

29.91

11.96

0.26

2.5

0.05

*2/*5
*10/*10 DUP

1
0.75

2 (2.3)
1 (1.2)

72.39
41.01

9.00
8.20

0.17
0.11

7.5
5

0.14
0.06

*10/*41

0.75

4 (4.7)

96.90 (76.95–138.05)

9.69 (7.70–13.80)

0.20 (0.13–0.28)

10 (10–10)

0.20 (0.17–0.21)

*10/*10
*4/*10

0.5
0.25

24 (27.9)
1 (1.2)

55.95 (33.68–86.28)
44.38

8.33 (6.12–10.22)
8.88

0.15 (0.11–0.22)
0.16

7.5 (5–10)
5

0.16 (0.09–0.20)
0.09

*5/*10

0.25

9 (10.5)

90.37 (46.94–135.83)

9.04 (5.67–10.65)

0.15 (0.10–0.20)

10 (5–19)

0.19 (0.09–0.38)

Note: Data are presented as median (interquartile range) unless otherwise stated.
Abbreviation: DUP, duplication.

Table 3 CYP2D6 Activity Score, Plasma Donepezil Concentrations and Dose per Day (n = 86)
Plasma Donepezil

Concentration/

Concentration/

Dosea (mg/

Dose/Weight

Predicted

Concentrations

Dose (ng/mL/

Dose/Weight (ng/

day)

(mg/kg/day)

Score

Phenotype

(ng/mL)

mg/day)

mL/mg/kg/day)

2

NMs

*1/*1, *1/*2, *2/*2

8 (9)

66.47 (36.68–82.99)

6.65 (5.48–7.07)

0.12 (0.10–0.14)

10 (6.25–10)

0.17 (0.11–0.20)

1.5

NMs

*1/*41, *2/*14B, *2/*41

4 (5)

55.49 (43.69–115.10)

11.10 (8.74–13.04)

0.22 (0.19–0.26)

5 (5–8.75)

0.11 (0.10–0.18)

1.25

NMs

*1/*10, *2/*10

29 (34)

35.52 (17.34–62.52)

6.64 (5.14–9.27)

0.12 (0.10–0.20)

5 (2.5–8.75)

0.10 (0.05–0.14)

1

IMs

*1/*5, *2/*4, *2/*5

6 (7)

48.49 (23.36–88.99)

7.63 (5.01–11.21)

0.17 (0.10–0.22)

7.5 (2.5–10)

0.14 (0.06–0.21)

0.75

IMs

*10/*10 DUP, *10/*41

5 (6)

96.03 (55.80–124.62)

9.60 (7.63–12.46)

0.19 (0.11–0.25)

10 (7.5–10)

0.20 (0.11–0.21)

0.5

IMs

*10/*10

24 (28)

55.95 (33.68–86.28)

8.33 (6.12–10.22)

0.15 (0.11–0.22)

7.5 (5–10)

0.16 (0.09–0.20)

0.25

IMs

*4/*10, *5/*10

10 (12)

77.71 (41.27–124.90)

8.96 (6.03–10.58)

0.16 (0.11–0.20)

10 (5–17)

0.18 (0.09–0.38)

CYP2D6

CYP2D6

Activity

CYP2D6 Genotype

N (%)

Notes: Data are presented as median (interquartile range) unless otherwise stated. aKruskal Wallis test for differences of CY2D6 activity scores across all groups, p = 0.029.
Abbreviations: DUP, duplication; NMs, normal metabolizers (activity score of 1.25 ≤ x ≤ 2.25); IMs, intermediate metabolizers (activity score of 0 < x < 1.25)

patients24 with approximately half of them had CYP2D6*1/
*10 and CYP2D6*10/*10. On the other hand, our findings
were different to those found in other ethnic groups including
South/Central Asian, Middle East, Oceanian, African
American, African, Caucasian and American23 (Table 5).
However, only CYP2D6*10 was focused in those previous
studies16,24 and no consideration in regard to CYP2D6 activity
score was noted. Our study used a higher resolution technique
which simultaneously detects 19 nucleotide variants of
CYP2D6 and genotype data was translated into phenotype
using the CYP2D6 activity score system. Hence, the predicted
phenotypes reported in our study were highly accurate com
pared to the previous ones.

Pharmacogenomics and Personalized Medicine 2020:13

The majority of the participants in our Thai cohort had
CYP2D6 activity scores of 1.25 (34%), 0.5 (28%) and
0.25 (12%). When the activity scores were translated into
phenotypes, the participants were classified into NMs and
IMs. There were no UMs or PMs in this study which was
different from previous studies conducted in Italians,25
Indian26 and Japanese.27
The average trough plasma donepezil concentrations for
therapeutic doses of 5 or 10 mg donepezil were 25.9 and 50.6
ng/mL, respectively.9 Hefner et al also suggested that plasma
donepezil concentrations need to reach at least 50 ng/mL for
maximum clinical efficacy at therapeutic dosage of 5 and
10 mg/day.28 The overall median plasma donepezil
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Figure 1 Bar charts represent plasma donepezil concentrations and dose per day between CYP2D6 predicted phenotypes. (A) median plasma donepezil concentration (ng/
mL) between CYP2D6 normal and intermediate metabolizers (p = 0.038). (B) median plasma donepezil concentration/dose (ng/mL/mg/day) between CYP2D6 normal and
intermediate metabolizers (p > 0.05). (C) plasma donepezil concentration/dose/weight (ng/mL/mg/kg/day) between CYP2D6 normal and intermediate metabolizers (p >
0.05). (D) median donepezil dose (mg/day) between CYP2D6 normal and intermediate metabolizers (p = 0.035). (E) median donepezil dose/weight (mg/kg/day) between
CYP2D6 normal and intermediate metabolizers (p > 0.05).

concentration in this study was 50.12 ng/mL which is con
sistent with the suggested therapeutic level.
A high degree of variability in plasma donepezil concen
trations across genotypes and activity scores were seen but
these did not reach statistical difference. Regardless, NMs
showed significantly lower plasma donepezil concentrations
compared to those observed for IMs (41.15 vs 61.95 ng/mL,
p = 0.038). These findings were in line with those reported by
Zhong et al that plasma donepezil concentrations were 40 ng/
mL and 60 ng/mL in NMs and IMs, respectively.24 Taken
together, these results suggest that CYP2D6 enzyme activity
influences the metabolism of donepezil.
However, it remains controversial whether CYP2D6
activity impacts the efficacy of donepezil treatment or
not.16,24,25,27,29–31,33 For example, a study by Varsaldi

548

Powered by TCPDF (www.tcpdf.org)

Dovepress

submit your manuscript | www.dovepress.com

DovePress

et al conducted in 42 AD patients evaluated the impact
of CYP2D6 polymorphisms (CYP2D6*1, *2xN, *3, *4,
*5 and *6) on steady state plasma donepezil concentra
tions and its clinical outcomes. They reported that
CYP2D6 genotype influenced the metabolism of the drug
and the treatment outcomes.25 A larger study was carried
out in a group of Thai (n = 85)16 and Chinese (n = 110)24
patients; however, the patients in these studies were only
genotyped for CYP2D6*10 (100C>T, rs1065852) variant.
Despite this limitation, the investigators showed that the
responders had a higher prevalence of CYP2D6*1/*10 and
*10/*10 genotypes and higher levels of plasma donepezil
concentrations. The decreased function of the genotypes
and increased plasma drug levels were associated with
improved cognitive score.
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Table 4 Multivariate Analysis
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Independent Variables

Model 1

Model 2

Activity Score

Phenotype

(r2 = 0.50)

(r2 = 0.49)

β

p value

β

p value

(Constant)

−101.78

0.307

−85.60

0.392

Age

−0.55

0.435

−0.49

0.486

Sex

31.73

0.033

28.50

0.052

Weight

0.79

0.226

0.81

0.220

Hemoglobin

2.02

0.659

2.56

0.581

Creatinine

44.04

0.065

42.57

0.075

Albumin

−0.40

0.957

−1.58

0.834

Aspartate aminotransferase

0.99

0.255

0.71

0.424

Alanine aminotransferase

−0.75

0.252

−0.60

0.369

Dose per day

7.61

0.000

7.45

0.000

CYP2D6 activity score

−23.38

0.027

n/a

n/a

CYP2D6 predicted phenotype

n/a

n/a

−22.82

0.044

Note: Dependent variable: plasma donepezil concentration.

On the other hand, a study conducted by Chianella et al
assessed the effects of CYP2D6 genetic variation (ie,
CYP2D6*1, *1xN, *2, *2xN, *3, *4, *6, *9, *10, and
*41) on the metabolism of donepezil and galantamine in
171 Italian patients with AD. They also assessed the
genetic variation of butyrylcholine esterase (BCHE)
which metabolizes and also is targeted by rivastigmine.
The frequency of decreased and nonfunctional CYP2D6
alleles was higher in non-responders compared to respon
ders. Genetic variation in either gene, CYP2D6 or BCHE,
predicted clinical response in AD patients treated with
AChEIs.29 Another study by Miranda et al also showed
that the dose of AChEIs (donepezil, rivastigmine and
galantamine), the absence of the apolipoprotein E (ApoE)
ξ4 allele as a risk marker for AD, and CYP2D6 poly
morphisms were not correlated with clinical response.34
A more recent study by Coin et al showed that increased
plasma donepezil concentration at 9 months, but not drug

metabolizing enzyme activity, were associated with better
cognitive outcomes in AD patients. CYP2D6 and CYP3A4
activities were measured using probe drugs but no direct
genotyping was performed.30
Based on the above conflicting reports,24,25,27,29–31,33 the
current study was selectively conducted in dementia partici
pants with the same degree of disease severity with no other
major co-morbidities aiming to substantiate the effects of
CYP2D6 genetic variation on drug dose and plasma levels.
We demonstrated the relationships between genotypepredicted phenotype with donepezil dose and plasma con
centrations in the univariate analysis. However, the multi
variate analysis showed that dose has no effect on plasma
concentration of donepezil. On the other hand, CYP2D6
activity score and phenotype groups significantly predicted
plasma donepezil concentration (r2 = 0.50 and 0.49, respec
tively, Table 4). In contrast, Mori et al reported that dose and
age, but not CYP2D6 predicted phenotype, predicted the
plasma donepezil concentration.27 This finding is different
to our study due to the difference of the study population.
Mori et al’s study was conducted in patients with dementia
with Lewy bodies.
This study has some limitations. The cross-sectional
design displays associations, not causal relationships. The
sample size is relatively small and did not comprise UMs
or PMs. This may be due to the relative rarity of these
phenotypes in East Asians including Thais. Second, the
participants were classified into 16 genotypes but half of
the genotype groups had a few subjects so there was not
enough power to detect any significant differences in
plasma donepezil concentration between the genotype
groups. In addition, the participants who could not tolerate
donepezil may have been switched to other drugs and thus
were excluded from the study. Third, donepezil is also
metabolized through CYP3A4 and CYP3A5 pathways

Table 5 CYP2D6 Allele Frequencies in Different Populations
Allele

Functiona

This

Thai14

study

East

South/Central

Middle

Asian

Asian

East

Oceanian

African

African

Caucasianb

American

American

*1

Normal function

21.5

24.6

35.6

48.9

40.7

73

33.6

32.4

37.1

50.5

*2

Normal function

9.9

10.8

12.7

28.8

21.7

1.2

15.6

19.7

26.8

22.7

*4

No function

1.2

1.3

0.6

7.9

7.8

2.5

6.4

3.3

18.1

10.8

*5

No function

8.1

6.7

5.2

3.3

2.3

4.3

6.4

6.2

2.8

2.1

*10

Decreased function

54.7

49.6

42.4

17.4

3.5

2.5

4.1

6.6

2.8

2.6

*14Bc

Decreased function

0.6

0.1

0.8

0

0.2

0

0

0.2

0

0.3

*41

Decreased function

4.1

6.5

2.2

7.7

19.9

0.9

8.7

9.7

8.7

3.8

Notes: This table was adapted from PharmGKB.23 aFunction attributed to each allele according to PharmVar.19 bEuropean and North American. c*14B was assigned by
Luminex and corresponds to *14 in PharmVar.19
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and several other genes including ABCB1, POR, NR1/2
have been reported to be involved in donepezil
disposition.26,30,35,36 However, a study in Thai population
reported that those pathways and drug transporters played
minimal roles in donepezil disposition and did not affect
treatment outcome.16 Fourth, drug levels may also be
affected by co-medications that are enzyme inducers or
inhibitors. Although co-medications of the participants
were reviewed and no potent enzyme inducers or inhibi
tors were identified, drug interactions cannot be comple
tely ruled out. Also, a previous study reported that plasma
concentrations of S-donepezil influence treatment
outcome.17 Here, we measured racemic plasma donepezil
concentrations as we would like to implement our findings
into the real clinical setting were the measurement of
stereoselective form of drug was not available in every
hospital. Lastly, only sixteen common CYP2D6 variants
were detected. However, undetected rare alleles would
likely not have altered our conclusions.

Conclusion
In a cohort of Thai dementia participants with the same
disease severity, we observed the relationships between
CYP2D6 genotype-predicted phenotype and donepezil
dose as well as the plasma concentration. NMs have
lower plasma donepezil concentrations compared to IMs.
The results from the multivariate analysis showed that
independent of dose, CYP2D6 activity score and pheno
type significantly predicted plasma donepezil concentra
tion. Additional studies with a larger sample size utilizing
next-generation sequencing are needed in order to confirm
whether the patients would benefit from pharmacogeneticguided treatment with donepezil or not.
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